Search results
Results From The WOW.Com Content Network
Phosphodiesterase-5. A phosphodiesterase inhibitor is a drug that blocks one or more of the five subtypes of the enzyme phosphodiesterase (PDE), thereby preventing the inactivation of the intracellular second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) by the respective PDE subtype(s).
Inhibitors of PDE can prolong or enhance the effects of physiological processes mediated by cAMP or cGMP by inhibition of their degradation by PDE. [13] Sildenafil (Viagra) is an inhibitor of cGMP-specific phosphodiesterase type 5, which enhances the vasodilatory effects of cGMP in the corpus cavernosum and is used to treat erectile dysfunction.
Most of the PDE families are composed of more than one gene. PDE3 is clinically significant because of its role in regulating heart muscle, vascular smooth muscle and platelet aggregation. PDE3 inhibitors have been developed as pharmaceuticals, but their use is limited by arrhythmic effects and they can increase mortality in some applications.
8654 242202 Ensembl ENSG00000138735 ENSMUSG00000053965 UniProt O76074 Q8CG03 RefSeq (mRNA) NM_033437 NM_001083 NM_033430 NM_153422 RefSeq (protein) NP_001074 NP_236914 NP_246273 NP_700471 Location (UCSC) Chr 4: 119.49 – 119.63 Mb Chr 3: 122.52 – 122.65 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Cyclic guanosine monophosphate-specific phosphodiesterase type 5 is an enzyme (EC ...
The United States Air Force provides a continuum of professional military education at Air University with Basic Developmental Education (BDE), Primary Developmental Education (PDE), Intermediate Developmental Education (IDE), and Senior Developmental Education (SDE). [1]
Chemical structure of sildenafil (Viagra), the prototypical PDE5 inhibitor. A phosphodiesterase type 5 inhibitor (PDE5 inhibitor) is a vasodilating drug that works by blocking the degradative action of cGMP-specific phosphodiesterase type 5 (PDE5) on cyclic GMP in the smooth muscle cells lining the blood vessels supplying various tissues.
EHNA is also a very potent adenosine deaminase inhibitor with an IC 50 ~2 nM. [13] This dual inhibition would lead to the accumulation of the two inhibitory metabolites, adenosine [13] [14] and cGMP, [12] [15] which may act in synergy to mediate diverse pharmacological responses including anti-viral, anti-tumour and anti-arrhythmic effects. [11]
Similarly to a final-value problem for a parabolic PDE, an initial-value problem for a backward parabolic PDE is usually not well-posed (solutions often grow unbounded in finite time, or even fail to exist). Nonetheless, these problems are important for the study of the reflection of singularities of solutions to various other PDEs.